A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).
Small Cell Lung Carcinoma
DRUG: Rovalpituzumab Tesirine
Change in QTcF interval from baseline QTcF following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors., 12 weeks
Change in RR interval from baseline RR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors., 12 weeks|Change in PR interval from baseline PR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors., 12 weeks|Change in QRS duration interval from baseline QRS duration following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors., 12 weeks|Change in waveform composition interval from baseline waveform composition following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors., 12 weeks|Relationship between plasma rovalpituzumab tesirine concentration and change in QTcF interval from baseline., 12 weeks|Incidence of proarrhythmic adverse events stratified by change in QTcF from baseline of less than 10 ms or greater than 10 ms., 12 weeks|Incidence of adverse events., From first dose through 30 days post-last-dose|Objective response rate, Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.|Duration of response, Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.|Progression free survival, Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.|Overall survival, Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.|Clinical benefit ratio, Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.|Maximum Plasma Concentration (Cmax), Cycles 1 and 2: Day 1 (predose, 30 min, 2 and 4 hours postdose) and days 2,3,4,8,15,and 29; Cycles 4,5,7,8: Day 1 predose and 30 min postdose.|Area Under the Curve (AUC), Cycles 1 and 2: Day 1 (predose, 30 min, 2 and 4 hours postdose) and days 2,3,4,8,15,and 29; Cycles 4,5,7,8: Day 1 predose and 30 min postdose.
Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).